Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 901–1,000 of 1,006
Razavi, S. E., Ramezani, A., Kazemi, A., & Attar, A. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/8317011 · Cited by 20
“While in the Colchicine Cardiovascular Outcomes Trial (COLCOT), colchicine showed promising benefits for secondary prevention of major cardiovascular events (MACE) [12], in the Australian COPS trial, contrary results were observed [20].”
BackgroundMethodResultInfluentialPan, Z., Cheng, J., Yang, W., Chen, L., & Wang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175068 · Cited by 25
Traditional and Emerging Sex-Specific Risk Factors for Cardiovascular Disease in Women
Mehta, P. K., Gaignard, S. M., Schwartz, A. M., & Manson, J. E. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308288 · Cited by 29
“Modulating the inflammatory response to reduce CVD risk has been studied in several clinical trials using agents such as canakinumab and colchicine [137–139].”
Backgroundvan Broekhoven, A., Mohammadnia, N., Silvis, M. J. M., Los, J., Fiolet, A. T. L., Opstal, T. S. J., Mosterd, A., Eikelboom, J. W., Nidorf, S. M., Budgeon, C. A., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01209-8 · Cited by 23
Xue, C., Chen, Q., Bian, L., Yin, Z., Xu, Z., Zhang, H., Zhang, Q., Zhang, J., Wang, C., Du, R., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.905363 · Cited by 23
Zu, Z., Sheng, J., Qi, J., Yu, M., Zhang, Y., Zheng, T., Xiang, K., Wu, H., Lu, G., & Zhang, L. J. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202212748 · Cited by 21
Greco, A., Finocchiaro, S., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2171788 · Cited by 23
Kim, S. H., Lee, K. Y., & Chang, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065556 · Cited by 24
Insights into the Role of Inflammation in the Management of Atherosclerosis
Rocha, V. Z., Rached, F. H., & Miname, M. H. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s276982 · Cited by 22
“5 mg/day could prevent the composite of myocardial infarction (MI), stroke, urgent hospitalization for angina leading to unplanned coronary revascularization, or death from cardiovascular causes in 4745 participants recruited within 30 days of MI.(8) Colchicine led to a 23% reduction in the primary endpoint (HR 0.”
BackgroundResultInfluentialHMGB family proteins: Potential biomarkers and mechanistic factors in cardiovascular diseases
Zheng, X., Lu, J., Liu, J., Zhou, L., & He, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115118 · Cited by 24
Inflammation and cholesterol at the crossroads of vascular risk
Verma, S., Mazer, C. D., & Connelly, K. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.011 · Cited by 21
Chen, T., Liu, G., & Yu, B. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02254-9 · Cited by 24
“What is more, some RCTs and meta-analyses indicated the use of colchicine in patients with CAD may be associated with a significant increase in non-cardiovascular mortality [18–21].”
BackgroundResultInfluentialChen, Q., Xiong, S., Zhang, Z., Yu, X., Chen, Y., Ye, T., Yang, S., Qi, L., Chen, X., Liu, H., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02011-2 · Cited by 24
“…(PCI), along with improvements in medical therapies such as dual antiplatelet therapy (DAPT) and intensive lipid-lowering therapy, there has been a notable decrease in mortality resulting from primary ischemic events for patients with coronary heart disease (CHD) over the past decade [1].”
BackgroundGendelman, O., Shapira, R., Tiosano, S., Pras, E., Comaneshter, D. S., Cohen, A. D., & Amital, H. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13473 · Cited by 21
Jia, X., Rifai, M. A., Hussain, A., Martin, S. S., Agarwala, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00895-z · Cited by 27
Folsom, A. R., & Cushman, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.019395 · Cited by 22
McEwan, T., & Robinson, P. C. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.007 · Cited by 21
“associations of infections with colchicine usage [41, 42].”
InfluentialChoi, H. K., Neogi, T., Stamp, L. K., Terkeltaub, R. A., & Dalbeth, N. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41638 · Cited by 21
Precision Medicine Approaches to Vascular Disease
Miller, C. L., Kontorovich, A., Hao, K., Ma, L., Iyegbe, C. O., Björkegren, J., & Kovacic, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.001 · Cited by 24
Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?
Sagris, Μ., Theofilis, P., Antonopoulos, A. S., Oikonomou, E. K., Tsioufis, K., & Tousoulis, D. (2022) · Biomedicines · doi:10.3390/biomedicines10020242 · Cited by 23
“Colchicine’s anti-inflammatory properties are based on two mechanisms: (a) direct inhibition of (NOD)-like receptor protein 3 (NLRP3) inflammasome and, consequently, of IL1β production, and (b) inhibition of the polymerization of microtubes [87].”
BackgroundBrambilla, M., Becchetti, A., Rovati, G. E., Cosentino, N., Conti, M., Canzano, P., Giesen, P. L. A., Loffreda, A., Bonomi, A., Cattaneo, M., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319099 · Cited by 22
Role of chemokines in aging and age-related diseases
Chaudhary, J. K., Danga, A. K., Kumari, A., Bhardwaj, A., & Rath, P. C. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.112009 · Cited by 30
Tucker, B., Tucker, W. J., Chung, J. S., Figtree, G. A., KEECH, A. C., & Patel, S. V. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf302 · Cited by 20
Hartley, A., Rostamian, S., Kaura, A., Chrysostomou, P., Welsh, P. I., Ariti, C. A., Sattar, N. A., Sever, P., & Khamis, R. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105786 · Cited by 31
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 36
Nowak, K. L., & Chonchol, M. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.06.019 · Cited by 30
Chen, H., Tang, Y., Ren, P., & Wu, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693441 · Cited by 30
The year in cardiology: cardiovascular prevention
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz929 · Cited by 20
Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?
Gelosa, P., Castiglioni, L., Camera, M., & Sironi, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113894 · Cited by 22
Ullah, W., Gowda, S. N., & Fischman, D. L. (2020) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2020.06.004 · Cited by 20
Keyes, E., Grinnell, M., Jacoby, D. S., Vazquez, T., Diaz, D., Werth, V. P., & Williams, K. J. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.08.015 · Cited by 21
Jarr, K.-U., Kojima, Y., Weissman, I. L., & Leeper, N. J. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317049 · Cited by 25
Ghang, B., Lee, J. S., Choi, J., Kim, J., & Yoo, B. (2022) · RMD Open · doi:10.1136/rmdopen-2021-001944 · Cited by 23
“This may be particularly important as ethical considerations make it difficult to conduct prospective studies on determining MACE risk on drug discontinuation.”
Poredoš, P., Šabovič, M., Mijovski, M. B., Starčević, J. N., Antignani, P. L., Paraskevas, K. I., Mikhailidis, D. P., & Blinc, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912054 · Cited by 24
“Colchicine reduces the levels of pro-inflammatory cytokines and stabilizes the coronary plaques, leading to a reduction of recurrent coronary events after acute coronary syndromes and better outcomes in patients with chronic coronary disease [57,58].”
BackgroundDrug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities
Chaffey, L., Roberti, A., & Greaves, D. R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1046406 · Cited by 24
“The COLCOT study of 4,445 patients found a significant reduction in adverse CV events in post-MI patients receiving daily colchicine versus those receiving placebo (Tardif et al., 2019).”
Angina in 2022: Current Perspectives
Manfredi, R., Verdoia, M., Compagnucci, P., Barbarossa, A., Stronati, G., Casella, M., Russo, A. D., Guerra, F., & Ciliberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236891 · Cited by 27
Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?
Rakočević, J., Dobric, M. R., Labudović‐Borović, M., Milutinović, K., Milenkovic, S., & Tomasevic, M. V. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401010 · Cited by 25
“Two possible explanations for differences in infection emerged: one might be due to the play of chance, and other might be the immunologic response to colchicine [56].”
BackgroundInfluentialZhang, J., Ji, C., Zhai, X., Tong, H., & Hu, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1038738 · Cited by 25
“The COLCOT (137) published in 2019 is a large randomized controlled trial (RCT) evaluating the effect of the colchicine group (0.5 mg/day) on recurrent cardiovascular events in patients who had a myocardial infarction within 30 days.”
BackgroundInfluentialWang, J., Liu, Y., Hu, J., & Chen, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1109576 · Cited by 26
“Although anti-inflammatory medications, such as canakinumab and colchicine, have been recently proven to lower the risk of CVD, there are still significant side effects and a high residual risk (Ridker et al., 2017; Tardif et al., 2019).”
BackgroundDenegri, A., Magnani, G., Kraler, S. C., Bruno, F., Klingenberg, R., Mach, F., Gencer, B., Räber, L., Rodondi, N., Rossi, V. A., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.043 · Cited by 21
Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice
Molnár, A., Pásztor, D. T., Tarcza, Z., & Merkely, B. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417129 · Cited by 27
Tian, X., Zhang, N., Korantzopoulos, P. G., Bazoukis, G., Letsas, Κ. P., Tse, G., & Liu, T. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132068 · Cited by 21
New Modifiable Risk Factors Influencing Coronary Artery Disease Severity
Florek, K., Kubler, M.-D., Górka, M., & Kübler, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147766 · Cited by 29
“Inflammation CRP [26–32] ACS Canakinumab [29], colchicine [30,31] RCTs-CANTOS [29], COLCOT [30], LoDoCo2 [31] NLR ACS [39,40]/ declined [44]/ only in males [46] SII Stable angina and ACS [46,52] UAR NSTEMI Microbiota Lactobacillus abundance ACS [69,72] Lactobacillus gasseri supplementation [73] RCT…”
BackgroundMethodInfluentialLaudani, C., Occhipinti, G., Greco, A., Giacoppo, D., Spagnolo, M., & Capodanno, D. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae100 · Cited by 28
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
Dubé, M., Legault, M., Lemaçon, A., Perreault, L. L., Fouodjio, R., Waters, D. D., Kouz, S., Pinto, F. J., Maggioni, A. P., Díaz, R., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003183 · Cited by 21
Self-citationWang, Y., Peng, X., Hu, J., Luo, T., Wang, Z., Cheng, Q., Mei, M., He, W., Peng, C. X., Ma, L., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13174 · Cited by 21
Evolution and Outcomes of Premature Coronary Artery Disease
Smith, C. L., Seigerman, M. E., Adusumalli, S., Giri, J. S., Fiorilli, P. N., Kolansky, D. M., & Kobayashi, T. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01457-8 · Cited by 25
Ca2+ mishandling in heart failure: Potential targets
Val‐Blasco, A., Fernández, M. G., Rueda, A., Pereira, L., Delgado, C., Smani, T., Ruiz‐Hurtado, G., & Fernández‐Velasco, M. (2021) · Acta Physiologica · doi:10.1111/apha.13691 · Cited by 22
Tardif, J., & Kouz, S. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuae135 · Cited by 34
Self-citationNeuroinflammation in kidney disease and dialysis
Chagas, Y. E. W., de Castro, P. A. S. V., & Silva, A. C. S. E. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115465 · Cited by 21
Zimerman, A., Kunzler, A. L. F., Weber, B., Ran, X., Murphy, S. A., Wang, H., Honarpour, N., KEECH, A. C., Sever, P., Sabatine, M. S., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072756 · Cited by 22
“4,32,37 38–41 Our data further extend these observations by supporting the concept that hyperlipidemia and inflammation are not only additive, 42,43 but synergistic, and that the increased risk attributable to inflammation can potentially be mitigated by intensive lipid lowering alone.”
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease
Finocchiaro, S., Mazzone, P. M., Ammirabile, N., Bordonaro, C., Cusmano, C., Cutore, L., Leo, G. D., Faro, D. C., Giacoppo, D., Greco, A., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf058 · Cited by 28
“37 After a median follow-up of 22.6 months, colchicine significantly reduced the incidence of the primary composite endpoint, primarily due to a decrease in stroke and urgent revascularization for angina; however, the rates of recurrent MI did not differ significantly be-tween groups.”
InfluentialCozac, D. A., Halațiu, V.-B., & Scridon, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630410 · Cited by 25
Inflammasomes: a preclinical assessment of targeting in atherosclerosis
Stitham, J., Rodríguez-Vélez, A., Zhang, X., Jeong, S., & Razani, B. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1795831 · Cited by 21
VIu, M., Orlova, Y. A., Павликова, Е. П., Akopyan, Z. A., Мацкеплишвили, С. Т., Геннадьевна, П. А., Seredenina, E. M., Potapenko, A. V., Малахов, П. С., Samokhodskaya, L. M., et al. (2020) · Kardiologiia · doi:10.18087/cardio.2020.9.n1338 · Cited by 22
Klingenberg, R., Aghlmandi, S., Gencer, B., Nanchen, D., Räber, L., Carballo, D., Carballo, S., Stähli, B. E., Landmesser, U., Rodondi, N., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.01.012 · Cited by 22
Immuno-metabolic interfaces in cardiac disease and failure
Bertero, E., Dudek, J., Cochain, C., Delgobo, M., Ramos, G. C., Gerull, B., Higuchi, T., Vaeth, M., Zernecke, A., Frantz, S., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab036 · Cited by 21
Gupta, K., Kalra, R., Pate, M., Nagalli, S., Ather, S., Rajapreyar, I. N., Arora, P. K., Gupta, A., Zhou, W., Estépar, R. S. J., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.11.027 · Cited by 19
Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease
Lázaro, A. M. P., Blanco‐Colio, L. M., Peláez, J. A. F., & Tuñón, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132835 · Cited by 22
“First, all patients were randomized during hospitalization while in COLCOT the median interval from ACS to inclusion was 14 days.”
BackgroundInfluentialMazzucchelli, R., Rodríguez‐Martín, S., García-Vadillo, A., Gil, M., Rodríguez, A., Barreira‐Hernández, D., García‐Lledó, A., & de Abajo, F. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253932 · Cited by 19
Jamialahmadi, T., Emami, F., Bagheri, R. K., Alimi, H., Bioletto, F., Bo, S., Aminzadeh, B., Ansari, M. A., Ehsani, F., Rajabi, O., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112632 · Cited by 23
Targeting Microtubules for the Treatment of Heart Disease
Warner, E. F., Li, Y., & Li, X. (2022) · Circulation Research · doi:10.1161/circresaha.122.319808 · Cited by 24
Zhang, J., Wang, X., Tian, W., Wang, T., Jia, J., Lai, R., Wang, T., Zhang, Z., Song, L., Ju, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.936817 · Cited by 21
“, canakinumab (6) and colchicine (7, 8)] confirmed the direct vasculo-protective effects of primarily targeting inflammation, which may partly explain the residual risk after the normalization of LDL-C.”
BackgroundParry, R., Majeed, K., Pixley, F. J., Hillis, G. S., Francis, R. J., & Schultz, C. J. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac167 · Cited by 19
“5 mg once daily).(39) Patients with recent myocardial infarction were randomized to either placebo or colchicine in addition to guideline-directed medical therapy.”
MethodPham, V., Moroni, A., Gall, E., Benedetti, A., Zivelonghi, C., & Picard, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082833 · Cited by 28
“) proved to be beneficial in reducing CRP levels and MACE rate in patients with prior MI and persistent inflammatory residual risk [66,67].”
BackgroundWang, Y., Li, J., Johnston, S. C., Hankey, G. J., Easton, J. D., Meng, X., Shi, F., Wang, Y., Zhao, X., Li, Z., et al. (2023) · International Journal of Stroke · doi:10.1177/17474930231172312 · Cited by 19
New Insights into Pathophysiology and New Risk Factors for ACS
Nardin, M., Verdoia, M., Laera, N., Cao, D., & Luca, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082883 · Cited by 26
“The promising results observed in the CANTOS trial [78] and COLCOT trial [79] should drive future intervention and research in inflammatory regulation among ACS patients (Table 1).”
BackgroundResultBiomarker and genomic analyses reveal molecular signatures of non-cardioembolic ischemic stroke
Ding, L., Liu, Y., Meng, X., Jiang, Y., Lin, J., Cheng, S., Xu, Z., Zhao, X., Li, H., Wang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01465-w · Cited by 27
“Recently, antiinflammatory agents, such as colchicine, have been shown to play a prominent role in improving cardiovascular outcomes in clinical trials.(21) Our study supports anti-inflammatory treatment as a promising therapy for ischemic stroke.”
BackgroundHeo, R., Wang, M. K., Meyre, P. B., Birchenough, L., Park, L., Vuong, K., Devereaux, P. J., Blum, S., Lindahl, B., Stone, G. W., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.021 · Cited by 28
Zhou, Y., Liu, Y., Zeng, R., Qiu, W., Zhao, Y., & Zhou, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1194605 · Cited by 20
“61; I(2) = 86%) via eliminating COLCOT (31).”
MethodColchicine in atherosclerotic cardiovascular disease
Tucker, B., Goonetilleke, N., Patel, S., & KEECH, A. C. (2024) · Heart · doi:10.1136/heartjnl-2023-323177 · Cited by 27
“24 25 In both LoDoCo trials, post-CABG patients were only eligible if the graft surgery was more than 10 years earlier, or they had evidence of graft failure or had undergone percutaneous coronary intervention since their operation.”
BackgroundInfluentialNorhammar, A., Näsman, P., Buhlin, K., Fairé, U. D., Ferrannini, G., Gustafsson, A. K., Kjellström, B., Kvist, T., Jäghagen, E. L., Lindahl, B., et al. (2024) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.14064 · Cited by 28
“Pharmacological agents counteracting such activation have been shown to reduce coronary events (Ridker et al. 2017; Tardif et al. 2019).”
Awaya, T., Hara, H., & Moroi, M. (2024) · Diseases · doi:10.3390/diseases12100231 · Cited by 19
“Since IL-1 β is involved in immune activation and antibody production [39], the use of colchicine may potentially suppress these functions, leading to a slightly higher risk of infections, such as pneumonia [40].”
BackgroundInfluentialThe Role of Colchicine in Atherosclerotic Cardiovascular Disease
Kurup, R., Galougahi, K. K., Figtree, G. A., Misra, A., & Patel, S. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.11.010 · Cited by 21
Nelson, T. A., Parker, W. A., Lakic, T. G., Westerbergh, J., James, S. K., Siegbahn, A. G., Becker, R. C., Himmelmänn, A., Wallentin, L. C., & Storey, R. F. (2021) · Platelets · doi:10.1080/09537104.2021.1934667 · Cited by 19
Zhang, X., Zhao, D., Feng, J., Yang, X., Lan, Z., Yang, T., Kong, X., Qu, H., & Zhou, H. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5518083 · Cited by 20
Carotid Atheroinflammation Is Associated With Cerebral Small Vessel Disease Severity
Evans, N. R., Tarkin, J. M., Walsh, J., Chowdhury, M. M., Patterson, A. J., Graves, M. J., Rudd, J. H. F., & Warburton, E. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.690935 · Cited by 19
Tang, Y., Shi, C., Qin, Y., Wang, S., Pan, H., Chen, M., Yu, X., Lou, Y., & Fan, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.804030 · Cited by 20
“The COLCOT study have demonstrated that colchicine can reduce the risk of recurring myocardial ischemic in patients after acute myocardial infarction and it has good safety in low dose (Tardif et al., 2019).”
BackgroundLicordari, R., Costa, F., Garcia-Ruiz, V., Mamas, M. A., Marquis‐Gravel, G., Hernández, J. M. D. L. T., Gómez‐Doblas, J. J., Jiménez-Navarro, M. F., Rodríguez‐Capitán, J., Urbano-Carrillo, C. A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071885 · Cited by 28
“Notably, an increased incidence of pneumonia was observed in the colchicine group, indicating a need for careful patient selection and monitoring [47].”
BackgroundBartoloni, E., Cacciapaglia, F., Erre, G. L., Gremese, E., Manfredi, A., Piga, M., Sakellariou, G., Spinelli, F. R., Viapiana, O., & Atzeni, F. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103760 · Cited by 18
Roles and mechanisms of ginsenoside Rg1 in coronary artery disease: Progress and perspectives
Zhang, L., Chen, P., Xu, L., & Guo, M. H. (2025) · Journal of Ginseng Research · doi:10.1016/j.jgr.2025.02.003 · Cited by 20
“Recent advancements in atherosclerosis treatment include medications like evolocumab [12], which reduces lipid accumulation, colchicine, targeting inflammation [13], and ticagrelor, inhibiting platelet aggregation [14].”
Mitsis, A., Sokratous, S., Karmioti, G., Kyriakou, M., Drakomathioulakis, M., Myrianthefs, M. M., Eftychiou, C., Kadoglou, N. P. E., Tzikas, S., Fragakis, N., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134795 · Cited by 29
“The COLCOT (Colchicine Cardiovascular Outcomes Trial) [84] and LoDoCo2 (Low-Dose Colchicine) [85] studies have compellingly highlighted the significant impact of low-grade inflammation on the prognosis of AMI patients in relation to future cardiovascular events.”
Zhu, H., Li, Z., Xu, X., Fang, X., Chen, T., & Huang, J. (2020) · PeerJ · doi:10.7717/peerj.9068 · Cited by 17
Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease
Teunissen, A. J. P., van Leent, M. M. T., Prévot, G., Brechbühl, E. E. S., Pérez‐Medina, C., Duivenvoorden, R., Fayad, Z. A., & Mulder, W. J. M. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315448 · Cited by 18
Stroke Genetics: Turning Discoveries into Clinical Applications
Dichgans, M., Beaufort, N., Debette, S., & Anderson, C. D. (2021) · Stroke · doi:10.1161/strokeaha.121.032616 · Cited by 21
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
Roubille, F., Merlet, N., Busseuil, D., Ferron, M., Shi, Y., Mihalache-Avram, T., Mecteau, M., Brand, G., Rivas, D., Cossette, M., et al. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.08.008 · Cited by 19
“5 mg colchicine daily in comparison with placebo provided large relative risk reductions of ischemic cardiovascular events in adults who had experienced a myocardial infarction or had chronic coronary disease [12,13].”
BackgroundSelf-citationColchicine Against SARS-CoV-2 Infection: What is the Evidence?
Drosos, A. A., Pelechas, E., Drossou, V., & Voulgari, P. V. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00425-0 · Cited by 18
Time‐Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk
Yoshida, K., Harrold, L. R., Middaugh, N., Guan, H., Stryker, S., Karis, E., & Solomon, D. H. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11432 · Cited by 19
“did not decrease CV risk among patients without RA with elevated CV risk (48), whereas IL-1β inhibition (canakinumab (15), colchicine (16,17)) showed more promise.”
BackgroundIribarren, A., Diniz, M. A., Merz, C. N. B., SHUFELT, C. L., & Wei, J. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106762 · Cited by 20
Drozd, M., Pujades‐Rodríguez, M., Morgan, A. W., Lillie, P. J., Witte, K. K., Kearney, M. T., & Cubbon, R. M. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac186 · Cited by 24
“Inflammation is a key driver of atherosclerosis [1, 15], and these trials demonstrated clinically important reductions in adverse cardiovascular events, yet without improving overall mortality [9, 10].”
BackgroundInfluentialColchicine for Coronary Artery Disease: A Review
Chen, T., Liu, G., & Yu, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.892588 · Cited by 21
“The result showed the primary end point, stroke, urgent hospitalization for angina leading to coronary revascularization was significant lower in the colchicine group compared with the placebo group (49).”
BackgroundInfluentialAl‐Awsi, G. R. L., Lafta, M. H., Kzar, H. H., Самиева, Г. У., Alsaikhan, F., Ahmad, I., Saleh, M. M., Altoum, A. A., Surendar, A., Mustafa, Y. F., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109318 · Cited by 21
Systematic review of colchicine neuromyopathy: Risk factors, duration and resolution
McEwan, T., Bhambra, J., Liew, D. F. L., & Robinson, P. C. (2022) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2022.152150 · Cited by 18
Chen, R., Li, J., Zhou, J., Wang, Y., Zhao, X., Li, N., Liu, W., Liu, C., Zhou, P., Chen, Y., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106618 · Cited by 18
Negative Impact of TET2 Mutations on Long-Term Survival After Transcatheter Aortic Valve Replacement
Lassalle, F., Duployez, N., Vincent, F., Rauch, A., Denimal, T., Rosa, M., Labreuche, J., Dombrowicz, D., Staels, B., Preudhomme, C., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.04.010 · Cited by 22
Bertero, E., Carmisciano, L., Jonasson, C., Butler, J., Maack, C., & Ameri, P. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae089 · Cited by 18
Mitsis, A., Kyriakou, M., Sokratous, S., Karmioti, G., Drakomathioulakis, M., Myrianthefs, M. M., Ziakas, A., Tzikas, S., & Kassimis, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030701 · Cited by 21
“Published in 2019, the COLCOT trial investigated the use of colchicine in 4745 post-MI patients [57].”
MethodNovel strategies for targeting neutrophil against myocardial infarction
Jiang, K., Hwa, J., & Xiang, Y. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107256 · Cited by 23
Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction
Quinn, M., Zhang, R. Y. K., Bello, I., Rye, K., & Thomas, S. R. (2024) · Antioxidants · doi:10.3390/antiox13070788 · Cited by 25
“However, peroxidasin/VPO1 is upregulated in vivo in inflamed or diseased cardiovascular tissue including human and mouse abdominal aortic aneurysms [220], atherosclerotic lesions in apoE − / − mice [221] and in response to pathogenic stimuli, including angiotensin II [222,223].”
BackgroundTercan, H., van Broekhoven, A., Bahrar, H., Opstal, T. S. J., Cossins, B. C., Rother, N., Rodwell, L., Bekkering, S., Messaoudi, S. E., Riksen, N. P., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3394 · Cited by 22
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

